MAPT and Alzheimer disease: Though the examination of cerebrospinal fluid (CSF) and PET imaging provide the most reliable AD-related biomarkers of Aβ and tau in vivo (Engelborghs et al., 2008; Brier et al., 2016), the invasive sampling procedure of CSF and high cost of PET image hinder their application in clinical trials and population screening, especially in the preclinical stages of AD.